201 related articles for article (PubMed ID: 27216296)
1. A Zebrafish Model of 5q-Syndrome Using CRISPR/Cas9 Targeting RPS14 Reveals a p53-Independent and p53-Dependent Mechanism of Erythroid Failure.
Ear J; Hsueh J; Nguyen M; Zhang Q; Sung V; Chopra R; Sakamoto KM; Lin S
J Genet Genomics; 2016 May; 43(5):307-18. PubMed ID: 27216296
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Dutt S; Narla A; Lin K; Mullally A; Abayasekara N; Megerdichian C; Wilson FH; Currie T; Khanna-Gupta A; Berliner N; Kutok JL; Ebert BL
Blood; 2011 Mar; 117(9):2567-76. PubMed ID: 21068437
[TBL] [Abstract][Full Text] [Related]
3. 5q- syndrome.
Boultwood J; Pellagatti A; Wainscoat JS
Curr Pharm Des; 2012; 18(22):3180-3. PubMed ID: 22571696
[TBL] [Abstract][Full Text] [Related]
4. New insights into 5q- syndrome as a ribosomopathy.
Barlow JL; Drynan LF; Trim NL; Erber WN; Warren AJ; McKenzie AN
Cell Cycle; 2010 Nov; 9(21):4286-93. PubMed ID: 20980806
[TBL] [Abstract][Full Text] [Related]
5. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.
Kumar MS; Narla A; Nonami A; Mullally A; Dimitrova N; Ball B; McAuley JR; Poveromo L; Kutok JL; Galili N; Raza A; Attar E; Gilliland DG; Jacks T; Ebert BL
Blood; 2011 Oct; 118(17):4666-73. PubMed ID: 21873545
[TBL] [Abstract][Full Text] [Related]
6. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
Ebert BL; Pretz J; Bosco J; Chang CY; Tamayo P; Galili N; Raza A; Root DE; Attar E; Ellis SR; Golub TR
Nature; 2008 Jan; 451(7176):335-9. PubMed ID: 18202658
[TBL] [Abstract][Full Text] [Related]
7. Loss of
Chen C; Huang H; Yan R; Lin S; Qin W
G3 (Bethesda); 2019 Dec; 9(12):4149-4157. PubMed ID: 31619461
[TBL] [Abstract][Full Text] [Related]
8. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.
Boultwood J; Yip BH; Vuppusetty C; Pellagatti A; Wainscoat JS
Adv Biol Regul; 2013 Jan; 53(1):8-17. PubMed ID: 23031788
[TBL] [Abstract][Full Text] [Related]
9. L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q- syndrome in a TP53-independent way.
Narla A; Payne EM; Abayasekara N; Hurst SN; Raiser DM; Look AT; Berliner N; Ebert BL; Khanna-Gupta A
Br J Haematol; 2014 Nov; 167(4):524-528. PubMed ID: 25098371
[TBL] [Abstract][Full Text] [Related]
10. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
Ebert BL
Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
[TBL] [Abstract][Full Text] [Related]
11. Advances in the 5q- syndrome.
Boultwood J; Pellagatti A; McKenzie AN; Wainscoat JS
Blood; 2010 Dec; 116(26):5803-11. PubMed ID: 20733155
[TBL] [Abstract][Full Text] [Related]
12. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H
Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549
[TBL] [Abstract][Full Text] [Related]
13. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.
Payne EM; Virgilio M; Narla A; Sun H; Levine M; Paw BH; Berliner N; Look AT; Ebert BL; Khanna-Gupta A
Blood; 2012 Sep; 120(11):2214-24. PubMed ID: 22734070
[TBL] [Abstract][Full Text] [Related]
14. Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
Yip BH; Vuppusetty C; Attwood M; Giagounidis A; Germing U; Lamikanra AA; Roberts DJ; Maciejewski JP; Vandenberghe P; Mecucci C; Wainscoat JS; Pellagatti A; Boultwood J
Leukemia; 2013 Aug; 27(8):1760-3. PubMed ID: 23337929
[No Abstract] [Full Text] [Related]
15. Dyserythropoiesis of myelodysplastic syndromes.
Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M
Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603
[TBL] [Abstract][Full Text] [Related]
16. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
Schneider RK; Schenone M; Ferreira MV; Kramann R; Joyce CE; Hartigan C; Beier F; Brümmendorf TH; Germing U; Platzbecker U; Büsche G; Knüchel R; Chen MC; Waters CS; Chen E; Chu LP; Novina CD; Lindsley RC; Carr SA; Ebert BL
Nat Med; 2016 Mar; 22(3):288-97. PubMed ID: 26878232
[TBL] [Abstract][Full Text] [Related]
17. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
18. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.
Barlow JL; Drynan LF; Hewett DR; Holmes LR; Lorenzo-Abalde S; Lane AL; Jolin HE; Pannell R; Middleton AJ; Wong SH; Warren AJ; Wainscoat JS; Boultwood J; McKenzie AN
Nat Med; 2010 Jan; 16(1):59-66. PubMed ID: 19966810
[TBL] [Abstract][Full Text] [Related]
19. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
20. Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome.
Vlachos A; Farrar JE; Atsidaftos E; Muir E; Narla A; Markello TC; Singh SA; Landowski M; Gazda HT; Blanc L; Liu JM; Ellis SR; Arceci RJ; Ebert BL; Bodine DM; Lipton JM
Blood; 2013 Oct; 122(14):2487-90. PubMed ID: 23943650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
